Alembic Pharmaceuticals Limited — Important, 29-04-2025: Updates

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US FDA for its Oncology Formulation Facility (F-2) at Panelav after a successful inspection. This approval demonstrates the facility's compliance with regulatory standards, potentially improving market access and growth in the oncology segment. Positive financial implications are expected as the company positions itself to capitalize on opportunities in this lucrative market.